[to top of second column]
No injuries have been reported to date from Med Prep products, but the FDA says it is working with officials in New Jersey and Connecticut to determine the scope of contamination.
"We do not have reports of patient infections. However, due to a lack of sterility assurance at the facility and out of an abundance of caution, this recall is necessary to protect patients," Janet Woodcock, director of the FDA's drug center, said in a statement.
The New Jersey State Board of Pharmacy reached an agreement with the company on Friday to shut down all production and shipping of medications.
Med Prep produces liquid drug formulations that given to patients intravenously.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor